Hoffmann C, Macefield R C, Wilson N, Blazeby J M, Avery K N L, Potter S, McNair A G K
National Institute for Health Research Bristol Biomedical Research Centre, Bristol Centre for Surgical Research, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
Division of Surgery, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK.
Colorectal Dis. 2020 Dec;22(12):1862-1873. doi: 10.1111/codi.15347. Epub 2020 Oct 23.
Early phase studies are essential to evaluate new technologies prior to randomized evaluation. Evaluation is limited, however, by inconsistent measurement and reporting of outcomes. This study examines outcome reporting in studies of innovative colorectal cancer surgery.
Systematic searches identified studies of invasive procedures treating primary colorectal adenocarcinoma. Included were a random sample of studies which authors reported as 'new' or 'modified'. Outcomes were extracted verbatim and categorized using an existing framework of 32 domains relevant to early phase studies. Outcomes were classified as 'measured' (where there was an explicit statement to that effect or evidence that data collection had occurred) or 'mentioned but not measured' (where outcomes were discussed but data collection was not evident). Patterns of identified outcomes are described.
Of 8373 records, 816 were potentially eligible. Full-text review of a random sample of 218 studies identified 51 for inclusion of which 34 (66%) were 'new' and 17 (33%) were 'modified'. Some 2073 outcomes were identified, and all mapped to domains. 'Anticipated disadvantages' were most frequently identified [660 (32%) outcomes identified across 50 (98%) studies]. No domain was represented in all studies. Under half (944, 46%) of outcomes were 'measured'. 'Surgeon's/operator's experience of the innovation' was more frequently 'mentioned but not measured' [207 (18%) outcomes across 46 (90%) studies] than 'measured' [17 (2%) outcomes, 11 (22%) studies].
There is outcome reporting heterogeneity in studies of early phase colorectal cancer surgery. The adoption of core outcome sets may help to resolve these inconsistencies and enable efficient evaluation of surgical innovations.
在进行随机评估之前,早期研究对于评估新技术至关重要。然而,评估受到结果测量和报告不一致的限制。本研究调查创新性结直肠癌手术研究中的结果报告情况。
系统检索确定了治疗原发性结直肠腺癌的侵入性手术研究。纳入的是作者报告为“新的”或“改良的”研究的随机样本。逐字提取结果,并使用与早期研究相关的32个领域的现有框架进行分类。结果分为“测量的”(有明确表明或有数据收集证据的)或“提及但未测量的”(讨论了结果但无数据收集证据的)。描述已确定结果的模式。
在8373条记录中,816条可能符合条件。对218项研究的随机样本进行全文审查后,确定了51项纳入研究,其中34项(66%)是“新的”,17项(33%)是“改良的”。共确定了约2073个结果,所有结果都映射到各个领域。“预期缺点”是最常被确定的[在50项(98%)研究中确定了660个(32%)结果]。并非所有研究都涵盖所有领域。不到一半(944个,46%)的结果是“测量的”。“外科医生/操作者对创新的体验”被“提及但未测量”的情况[在46项(90%)研究中有207个(18%)结果]比“测量的”情况[17个(2%)结果,11项(22%)研究]更频繁。
早期结直肠癌手术研究中存在结果报告异质性。采用核心结局集可能有助于解决这些不一致性问题,并实现对外科创新的有效评估。